Literature DB >> 12629526

Expression of amphetamine-induced behavioral sensitization after short- and long-term withdrawal periods: participation of mu- and delta-opioid receptors.

Karin Magendzo1, Gonzalo Bustos.   

Abstract

Repeated amphetamine administration results in behavioral sensitization, an enduring behavioral transformation expressed after short and long periods of withdrawal. To investigate the participation of the opioid system in amphetamine-induced behavioral sensitization, we studied the effect of naloxone, an opioid receptor antagonist, on the expression of behavioral sensitization tested after short- (2 days) and long-term (14 days) withdrawal periods. In addition, using quantitative competitive RT-PCR, we examined the levels of mu-opioid receptor (MOR) and delta-opioid receptor (DOR) mRNA in the nucleus accumbens shell (NAcSh) and ventral tegmental area (VTA) of behaviorally sensitized rats, at these two withdrawal times. This study showed that whereas naloxone did not modify the expression of behavioral sensitization tested after 2 days of withdrawal, it completely blocked the expression when tested after 14 days of withdrawal. DOR and MOR mRNA levels were not modified in the NAcSh of rats expressing behavioral sensitization after 2 or 14 days of withdrawal. Conversely, DOR and MOR mRNA levels were elevated in the VTA of animals expressing behavioral sensitization after 2 days of withdrawal. However, whereas DOR mRNA returned to control levels, MOR mRNA levels remained elevated in animals expressing behavioral sensitization after 14 days of withdrawal. These results indicate a striking difference between the role played by opioid receptors in the expression of amphetamine-induced behavioral sensitization, when tested after short- or long-term withdrawal periods. In addition, our results support the notion that repeated amphetamine-induced changes in opioid receptor expression may contribute to the perpetuation of psychostimulant abuse and/or relapse.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12629526     DOI: 10.1038/sj.npp.1300063

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  11 in total

Review 1.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

2.  Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexone.

Authors:  Chi-Tso Chiu; Tangeng Ma; Ing K Ho
Journal:  Brain Res Bull       Date:  2005-09-30       Impact factor: 4.077

Review 3.  Gene expression in aminergic and peptidergic cells during aggression and defeat: relevance to violence, depression and drug abuse.

Authors:  Klaus A Miczek; Ella M Nikulina; Aki Takahashi; Herbert E Covington; Jasmine J Yap; Christopher O Boyson; Akiko Shimamoto; Rosa M M de Almeida
Journal:  Behav Genet       Date:  2011-03-17       Impact factor: 2.805

4.  Knockdown of ventral tegmental area mu-opioid receptors in rats prevents effects of social defeat stress: implications for amphetamine cross-sensitization, social avoidance, weight regulation and expression of brain-derived neurotrophic factor.

Authors:  Caitlin E Johnston; Daniel J Herschel; Amy W Lasek; Ronald P Hammer; Ella M Nikulina
Journal:  Neuropharmacology       Date:  2015-02       Impact factor: 5.250

5.  Methamphetamine-induced behavioral sensitization in mice: alterations in mu-opioid receptor.

Authors:  Chi-Tso Chiu; Tangeng Ma; Ing K Ho
Journal:  J Biomed Sci       Date:  2006-07-18       Impact factor: 8.410

Review 6.  Reward processing by the opioid system in the brain.

Authors:  Julie Le Merrer; Jérôme A J Becker; Katia Befort; Brigitte L Kieffer
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

7.  Long-lasting alteration in mesocorticolimbic structures after repeated social defeat stress in rats: time course of mu-opioid receptor mRNA and FosB/DeltaFosB immunoreactivity.

Authors:  Ella M Nikulina; Isabel Arrillaga-Romany; Klaus A Miczek; Ronald P Hammer
Journal:  Eur J Neurosci       Date:  2008-05       Impact factor: 3.386

Review 8.  Neurotrophins in the ventral tegmental area: Role in social stress, mood disorders and drug abuse.

Authors:  E M Nikulina; C E Johnston; J Wang; R P Hammer
Journal:  Neuroscience       Date:  2014-05-27       Impact factor: 3.590

9.  Feasibility, Acceptability, and Tolerability of Targeted Naltrexone for Nondependent Methamphetamine-Using and Binge-Drinking Men Who Have Sex with Men.

Authors:  Glenn-Milo Santos; Phillip Coffin; Deirdre Santos; Shannon Huffaker; Tim Matheson; Jason Euren; Anna DeMartini; Christopher Rowe; Judith A Hahn; David Vlahov; Eric Vittinghoff; Steven L Batki
Journal:  J Acquir Immune Defic Syndr       Date:  2016-05-01       Impact factor: 3.731

10.  MOP Reduction During Long-Term Methamphetamine Withdrawal was Restored by Chronic Post-Treatment with Fluoxetine.

Authors:  H Yamamoto; Y Takamatsu; K Imai; E Kamegaya; Y Hagino; M Watanabe; T Yamamoto; I Sora; H Koga; K Ikeda
Journal:  Curr Neuropharmacol       Date:  2011-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.